Shares of Sorrento Therapeutics (SRNE) have been on the backfoot for most of the year, retreating by 63% since the February peaks. Throughout the downturn, however, one Street analyst has been backing the biotech; H.C. Wainwright’s Ram Selvaraju thinks the stock is poised to claw back those gains and some. The analyst reiterated a Buy rating on SRNE, along with a $26 price target. If correct, investors could be lining their pockets with a huge 286% gain. (To watch Selvaraju’s track record, click here) Selvaraju’s latest endorsement follows a recent positive development.
https://www.tipranks.com/news/corona/sorrento-covid-19-tests-could-generate-significant-revenue-says-analyst?utm_source=advfn.com&utm_medium=referral
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Sorrento Therapeutics Charts.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Sorrento Therapeutics Charts.